Business Segments Lineage Cell Therapeutics, Inc.
Stocks
LCTX
US53566P1093
Biotechnology & Medical Research
|
Real-time Estimate
Cboe BZX
11:02:00 2026-10-01 EDT
|
5-day change | 1st Jan Change | ||
| 0.9270 USD | -3.00% |
|
-1.66% | -44.19% |
| 08-07 | Lineage Cell Therapeutics, Inc., Q2 2026 Earnings Call, Aug 06, 2026 | |
| 08-06 | Lineage Cell Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Research and Development of Therapeutic Products | 4.34M | 14.7M | 8.94M | 9.5M | 14.56M | |||||
Total Assets | 175M | 124M | 101M | 113M | 113M | |||||
Interest Expense | - | - | - | - | - | |||||
Income Tax Expense | - | 541K | -1.8M | - | -5.28M | |||||
CAPEX | -354K | -413K | -674K | -565K | -522K | |||||
EBT | -43.27M | -25.81M | -23.28M | -18.58M | -68.65M | |||||
Gross Profit | 2.92M | 13.98M | 8.27M | - | - | |||||
D&A | 887K | 727K | 692K | 609K | 699K | |||||
Operating Income | -49.21M | -22.52M | -24.73M | -21.48M | -36.62M | |||||
Net Income | -43.02M | -26.27M | -21.49M | -18.61M | -63.53M |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
United States | 3.9M | 14.7M | 8.94M | 9.5M | 14.56M | |||||
Total Assets | 548K | 1.38M | 827K | 1.48M | 949K | |||||
Foreign | 446K | - | - | - | - | |||||
Total Assets | 4.32M | 4.29M | 3.94M | 3.6M | 3.75M | |||||
Asia | - | - | - | - | - | |||||
| - | - | - | - | 14.56M |
- Stock Market
- Stocks
- LCTX Stock
- Financials Lineage Cell Therapeutics, Inc.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
